SAN DIEGO, June 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX) a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that the Company,
through its wholly owned subsidiary, ADVENTRX (Europe) Ltd., has received
notification from the European Medicines Agency (EMEA) that it has been
granted designation as a Small/Medium Enterprise (SME). Implemented in
November 2005, the SME program is an initiative by the EMEA that is
designed to assist small companies applying for European approval of
medicinal products. In addition to financial benefits afforded the
designation through lowered or reduced fees, the designation offers
participants access to substantial scientific advice during the clinical
development and application processes.
"We are pleased to have been granted designation as a Small/Medium
Enterprise and look forward to the advice and administrative assistance of
the EMEA as we continue to pursue clinical development opportunities in the
European Union," stated Evan M. Levine, chief executive of ADVENTRX.
ADVENTRX (Europe) Ltd. was incorporated in July 2004 in the United
Kingdom as a wholly-owned subsidiary of ADVENTRX Pharmaceuticals, Inc.,
primarily to facilitate conducting clinical trials in the European Union.
Additional information on the SME program is available from the EMEA
website at: http://www.emea.eu.int/SME/SMErelated.htm.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: uncertainties inherent in the drug development process; the
timing and success of clinical trials; the validity of research results;
the receipt of necessary approvals from the FDA and other regulatory
agencies; and other risks and uncertainties more fully described in
ADVENTRX's press releases and public filings with the Securities and
Exchange Commission. ADVENTRX's public filings with the Securities and
Exchange Commission are available at http://www.sec.gov. ADVENTRX does not intend
to update any forward-looking statement, including as set forth in this
press release, to reflect events or circumstances arising after the date on
which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
http://www.prnewswire.com/comp/920134.html /
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866
|
